Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers-Reference-Cited by-同舟云学术

Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers

Published:2018-11-17 Issue:2 Volume:68 Page:283-296
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Chiang Shu-Fen,Huang Chih-Yang^ORCID,Ke Tao-Wei,Chen Tsung-Wei,Lan Yu-Ching,You Ying-Shu,Chen William Tzu-Liang,Chao K. S. Clifford^ORCID

Funder

China Medical University Hospital

Ministry of Science and Technology, Taiwan

Ministry of Health and Welfare

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2275-0/fulltext.html

Reference47 articles.

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249. https://doi.org/10.3322/caac.20006

2. Conde-Muino R, Cuadros M, Zambudio N, Segura-Jimenez I, Cano C, Palma P (2015) Predictive biomarkers to chemoradiation in locally advanced rectal cancer. Biomed Res Int 2015:921435. https://doi.org/10.1155/2015/921435

3. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rodel C (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30(16):1926–1933. https://doi.org/10.1200/JCO.2011.40.1836

4. Yoon WH, Kim HJ, Kim CH, Joo JK, Kim YJ, Kim HR (2015) Oncologic impact of pathologic response on clinical outcome after preoperative chemoradiotherapy in locally advanced rectal cancer. Ann Surg Treat Res 88(1):15–20. https://doi.org/10.4174/astr.2015.88.1.15

5. Balko JM, Black EP (2009) A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer 9:145. https://doi.org/10.1186/1471-2407-9-145

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive study on the prognostic value and clinicopathological significance of different immune checkpoints in patients with colorectal cancer: a systematic review and meta-analysis;Current Therapeutic Research;2024-09

2. PD-L1 Expression in Paired Samples of Rectal Cancer;Cancers;2024-07-21

3. Immunotherapy and radiotherapy for older patients with locally advanced rectal cancer unfit for surgery or decline surgery: a practical proposal by the International Geriatric Radiotherapy Group;Frontiers in Oncology;2024-02-22

4. Prognostic Value of Immune Cells Subsets Within the Tumor Microenvironment in Patients With Rectal Adenocarcinoma;Anticancer Research;2024-02

5. Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer;Scientific Reports;2023-11-09